Clinical Research and Trials

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. Learn more about clinical trials by visiting clinicaltrials.gov

For more information on clinical studies, contact Beth Ann Brundage, RN, OCN, at 518-926-6644 or Nannette Oberhelman, at 518-926-6701.

Clinical Trials

ANAL

CTSU EA2165
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Ca

BLADDER

CTSU A031501 
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

CTSU S1937 
A Phase III Randomized Trial of Eribulin with or without Gemcitabine vs Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

BRAIN

CTSU    A071801  
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease

BREAST

CTSU A011801      
he CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

CTSU A221505-CHARM
Randomized trial testing the safety and patient experience of short course radiation after mastectomy and breast reconstruction for breast cancer

CTSU    EA1181        
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

CTSU NRG-BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer. (Also under Registries)

COLON

A021703
Randomized Double-Blind Phase III Trial of Vit. D3 Supplementation in Patients with Previously Untreated Met. Colorectal Ca (SOLARIS)

NRG GI005
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) (Temporary Suspension)

LEUKEMIA

CTSU A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

CTSU EA9161
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab vs Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

CTSU  S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab vs. DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

LUNG

SCLC Limited

LU005  
Limited Stage Small Cell Lung Cancer: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

NSCLC Limited

CTSU A151216  NSCLC
Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512 
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU A081801
Integration of immune-therapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

CTSU EA5181  
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alo

NSCLC Advanced

CTSU A171901
Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)

CTSU  LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

CTSU EA5182
Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer

CTSU EA5191  
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.

MDS

NHLBI-MDS 
The National Myelodysplastic Syndromes (MDS) Study: Recruiting Patients With Low Blood Counts Undergoing A Bone Marrow Assessment for Evaluation of MDS

MULTIPLE MYELOMA

CTSU EAA173   DETER-SMM
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

CTSU EAA181 
EQUATE: Effective Quadruplet Utilization After Treatment Evaluation – A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

PROSTATE

S1802  
Phase III Randomized Trial of Standard Systemic Therapy (SST) vs. Standard Systemic Therapy Plus Definitive Treatment (Surgery or RT) of the Primary Tumor in Met. Prostate Ca 

RENAL

A031704
Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

CTSU EA8143  
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

REGISTRIES

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

OTHER STUDIES

CTSU A221602 
Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

 

NOTE:  Other studies are available to us through the University of VT; we open them as Research Nurse identifies an eligible patient.

C.R. Wood Cancer Center
Research Office

Pruyn Pavilion at Glens Falls Hospital
2nd Floor
100 Park Street
Glens Falls, NY 12801

Phone: 518-926-6701
Fax: 518-926-1954

Clinical Trial Key:

A = Alliance

C = CALGB

E = ECOG

N = NSABP

NRG = NSABP/RTOG/GOG

P = Pharmacy

R = RTOG

S = SWOG

CTSU= NCI Cancer Trials Support Unit

VCC = Vermont Cancer Center

 

Updated 5/2021